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Abstract
Secretory carcinoma is a salivary gland tumor with a characteristic chromosomal translocation that results in an ETV6-
NTRK3 fusion gene. Secretory carcinoma shows relatively frequent rates of lymph-node metastasis and tumor recurrence and
has a characteristic histology. Except for the ETV6 translocation, genomic alterations in secretory carcinoma have not been
reported. In the present study, we characterized the novel recurrent genetic mutations of secretory carcinoma. On the basis of
histology, immunohistochemistry, and ETV6 gene break-apart fluorescence in situ hybridization assays, 22 tumors were
classified as secretory carcinomas (19 ETV6 translocation-positive and 3 ETV6 translocation-negative secretory carcinomas)
and their clinicopathologic characteristics were reviewed. Targeted deep sequencing analyses were performed on
20 secretory carcinomas (17 ETV6 translocation-positive and 3 ETV6 translocation-negative secretory carcinomas) to
investigate their genetic alterations. The A16V (C→T) mutation in PRSS1, which encodes a cationic trypsinogen and has a
mutation associated with hereditary pancreatitis and pancreatic adenocarcinoma, was observed in 40% (8/20) (7/17 of ETV6
translocation-positive and 1/3 of ETV6 translocation-negative secretory carcinomas). Pathogenic variants of MLH1,
MUTYH, and STK11 were also identified. Variants of uncertain significance included mutations in KMT5A. These novel
characteristic genetic alterations may advance current understandings of secretory carcinoma tumorigenesis and progression,
leading to improved diagnoses and treatment strategies.
Introduction
Secretory carcinoma is a recently described salivary gland
neoplasm characterized by the chromosomal translocation
t(12;15)(p13;q25), which results in the ETV6-NTRK3
fusion gene. This gene is identical to the one found in
secretory carcinoma of the breast, infantile fibrosarcoma,
and acute myeloid leukemia [1–3].
Since the description of secretory carcinoma as a new
disease entity, several studies have reported the clin-
icopathologic features of secretory carcinoma that allow
for its differential diagnosis from other subtypes of sali-
vary gland tumors, such as acinic cell carcinoma, adeno-
carcinoma—not otherwise specified, low-grade
mucoepidermoid carcinoma, and intraductal carcinoma, or
so-called low-grade cribriform cystadenocarcinoma. The
histologic features of secretory carcinoma include a
variety of architectural growth patterns, the presence of
intracytoplasmic vacuoles, mucin-like and colloid-like
eosinophilic secretions, and a lack of intracytoplasmic
periodic acid-Schiff+ (PAS+) zymogen granules. Immu-
nohistochemistry analyses have shown that most secretory
carcinomas are positive for S100 and mammaglobin and
negative for DOG1 [2, 4–15]. Secretory carcinoma reveals
relatively frequent rates of lymph node metastasis in as
many as 25% of cases at presentation [2]. This tumor
usually shows indolent clinical behaviors; however,
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aggressive courses, such as recurrence and death of dis-
ease, are also reported in some cases [1, 2, 4, 16–18].
Apart from the ETV6 gene translocation, little is known
about genomic alterations in secretory carcinoma. There-
fore, further studies of the novel recurrent genetic altera-
tions in secretory carcinoma are needed. In this study, we
characterized the genetic alterations in secretory carcinoma




The database of Severance Hospital Cancer Registry Data
(Seoul, South Korea) was searched to identify secretory
carcinoma candidates from salivary gland tumors ori-
ginally diagnosed as acinic cell carcinoma, adenocarci-
noma—not otherwise specified, various subtypes of
adenocarcinoma, and mucoepidermoid carcinoma.
Patients with other malignancies were not included. The
tumors were from patients treated and monitored at the
Yonsei University Health System Department of Otorhi-
nolaryngology. Patient medical records, pathology
reports, and clinical details were reviewed in accordance
with the Eighth American Joint Committee on Cancer
criteria [19]. The study was approved by the Severance
Hospital Institutional Review Board (Protocol No. 4-
2018-0816). Supplementary Fig. 1 shows a flowchart and
details of the study.
After an initial screening of histology and clinical data,
all cases of acinic cell carcinoma and adenocarcinoma not
otherwise specified in salivary glands were selected for
further screening. Two independent pathologists (KN and
SOY) reviewed all available stained slides by routine light
microscopy and selected the most representative formalin-
fixed paraffin-embedded block for ancillary tests. Histo-
logic classification followed the World Health Organiza-
tion classification criteria [2]. Candidate cases were
selected for ETV6 gene rearrangement fluorescence in situ
hybridization (FISH) analyses on the basis of having low-
grade nuclear features with bubbly eosinophilic cyto-
plasm, no zymogen granules, a positive staining for S100
and/or mammaglobin, and a negative staining for DOG1
and P63. Twenty two of the reviewed cases were con-
sidered to be secretory carcinoma. Among them,
19 secretory carcinomas harbored ETV6 translocation and
3 secretory carcinomas lacked ETV6 translocation. These
3 ETV6 translocation-negative cases, which were origin-
ally diagnosed as acinic cell carcinoma, had a histology
similar to that of secretory carcinoma in that they showed
microcystic, tubular, and papillary cystic architectures,
low-grade uniform nuclei, occasional small nucleoli,
pinkish bubbly cytoplasm, lack of PAS+zymogen gran-
ules, and mucin-like and colloid-like eosinophilic secre-
tions. They also displayed diffuse positive staining for
both S100 and mammaglobin and negative staining for
DOG1 and P63. These cases did not demonstrate features
favoring low-grade mucoepidermoid carcinoma, such as
squamoid differentiation or intracytoplasmic mucin. Also,
the lack of micropapillary or sieve-like fenestrated
architectures and the presence of invasive foci were dif-
ferent from typical histological features of low-grade
salivary duct carcinoma [2]. Given their present histolo-
gical features and immunophenotypes typical of secretory
carcinoma, these 3 cases were included as secretory car-
cinoma as suggested [20].
During the review process, we also reviewed 36 acinic
cell carcinoma cases. To further identify the characteristics
of secretory carcinoma that distinguish it as a clin-
icopathologically distinct disease entity, we compared the
clinical and histologic features of 22 secretory carcinomas
with those of the 36 cases of acinic cell carcinoma.
Tissue microarray preparation and
immunohistochemistry
To construct the tissue microarray, two different repre-
sentative tumor areas per sample were selected, and 3 mm
tissue cores were taken from formalin-fixed paraffin-
embedded donor tissue blocks and arranged in recipient
tissue microarray blocks using a trephine apparatus. A
Ventana Benchmark XT autostainer (Ventana Medical
Systems, Inc, Tucson, AZ, USA) was used to perform
immunohistochemistry analyses for mammaglobin (clone
31A5, 1:100; Cell Marque, Rocklin, CA, USA), S100
(clone Z0311, 1:2000; Dako, Glostrup, Denmark), DOG1
(clone SP31, Ready-to-Use; Cell Marque), p63 (clone
M7317, 1:200; Dako), and androgen receptor (RTU, clone
SP107; Cell Marque). The immunohistochemistry ana-
lyses were performed on 4 µm thick sections prepared
from the tissue microarray tissue blocks and representa-
tive formalin-fixed paraffin-embedded tissues when
necessary, in accordance with standard protocols [21].
Fluorescence in situ hybridization
FISH was performed on representative formalin-fixed par-
affin-embedded tissue sections using a commercially
available ETV6 dual-color break-apart probe (07j77-001;
Abbott Molecular, Des Plaines, IL, USA), as previously
described [22]. Cells with the ETV6 rearrangements had
split orange and green signals that were apart from each
other. Tumors were considered to be positive for ETV6 if
this rearrangement was found in >15% of cells.
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Targeted deep sequencing analyses
All targeted deep sequencing analyses (including related
experiments and genome analyses) were performed at Mac-
rogen (Seoul, South Korea). A customized panel (Axen
Cancer Master Panel, Macrogen) including 535 genes for
SNV/InDel, 54 genes for fusions, and 1 promoter gene was
designed and used for the targeted sequencing (See Supple-
mentary Table 1 for the entire list of genes) of 20 secretory
carcinoma samples (17 ETV6 translocation-positive and 3
ETV6 translocation-negative secretory carcinomas). Paired-
end sequencing (2 × 150 bp) was performed using a NextSeq
500 sequencer (Illumina, San Diego, CA, USA). Genome
analyses were performed to detect somatic short variants
following GATK (Genome Analysis Toolkit) Best Practices
[23]. The adapter sequences were removed using Cutadapt
[24]. The raw sequence reads in FASTQ files were mapped to
the UCSC hg19 human reference by using BWA-mem [25].
Poorly mapped reads with mapping quality values <20 were
removed using Samtools [26]. Picard MarkDuplicates (http://
broadinstitute.github.io/picard) were used to exclude PCR
artificial duplicates. Indel realignment and base quality score
recalibration were performed using GATK, and the Mutect2
algorithm in the GATK was used to call somatic single
nucleotide variants and indels [27]. False positive variant calls
originating from oxoG artifacts were excluded. In addition,
mutations with a variant allele frequency <3% and a 100×
total depth were excluded. Germline variants were excluded
when the minor allele frequency was ≥5% in the Exome
Aggregation Consortium (http://exac.broadinstitute.org/) or
the Macrogen Korean Population Database [28]. The func-
tional impacts of the variants were determined using SnpEff
v4.3 and SnpSift with dbNSFP v2.9.3 [29–31]. Variants were
further filtered using the following cut-off values: mutant
allele count <5 and an allele frequency in the normal popu-
lation (from dbSNP) >0.1 [32]. All remaining variants were
manually inspected by sequence analysis experts using the
Integrative Genomics Viewer [33]. The fusion genes were
analyzed using an in-house script (Macrogen) that was able to
discriminate plausible gene fusion events among the structural
variations predicted by LUMPY [34] and UMI Error Cor-
rection Local App 1.0.0.1 (Illumia; https://support.illumina.
com/downloads/umi-error-correction-local-app-documenta
tion.html). Copy number variations were analyzed using an
in-house script (Macrogen). The clinical significance of
genetic variants was determined on the basis of the ClinVar
variation report (https://www.ncbi.nlm.nih.gov/clinvar).
Statistical analyses of patient survival
The Kaplan–Meier method was used to analyze survival
rates, and differences were compared using the log-rank
test. Overall survival was measured from the date of
diagnosis to the date of death or last follow-up. Disease-free
survival was measured from the date of diagnosis to
cancer recurrence, continuance of stable disease/partial
remission/progressive disease without complete remission,
or cancer-related death during the study period. Two-sided
P values < 0.05 were considered statistically significant.
Statistical analyses were conducted using IBM SPSS
23 software for Windows (IBM Corp, Armonk, NY, USA).
Results
Histological features and clinical outcomes of
secretory carcinoma
The histopathologic and clinical features of the 22 secretory
carcinoma cases are represented in Figs. 1 and 2 and
summarized in Tables 1 and 2. The characteristics of the 36
acinic cell carcinoma cases are summarized for comparison
and represented in Fig. 2 and Tables 1 and 2. Details are
described in the Supplementary Appendix and Supple-
mentary Figs 2 and 3.
Histologically, papillary cystic growth was the most
common pattern observed in the secretory carcinoma cases
(64% [14/22]). The tumor cells showed low-grade uniform
nuclei, occasional small nucleoli, and pinkish bubbly
cytoplasm. PAS+ zymogen granules were not observed, but
mucin-like and colloid-like eosinophilic secretions were
easily observed. All secretory carcinomas were diffusely
stained for S100 in both the nuclei and cytoplasm, except
for one case with focal expression. Mammaglobin expres-
sion presented in 91% (20/22) of the secretory carcinomas
as a cytoplasmic staining pattern and showed diffuse
expression in 77% (17/22). None of the secretory carcino-
mas showed diffuse expression of DOG1 or p63. The ETV6
gene rearrangement was noted in 86% (19/22) in FISH
analyses (Table 1). Cervical lymph node dissection was
performed in 50% (11/22) of patients with secretory carci-
noma; among them, four had nodal metastasis. The Amer-
ican Joint Committee on Cancer tumor stage distribution of
our series was I (14% [3/22]), II (64% [14/22]), and III
(23% [5/22]). The median follow-up for patients with
secretory carcinoma was 46 months (range, 6-140 months).
During the follow-up period, 32% (7/22) of patients
experienced disease recurrence, including local (23% [5/
22]), nodal (5% [1/22]), and local and nodal disease (5% [1/
22]). The median interval period between surgery and
recurrence was 24 months (range, 6–51 months). None of
the patients died from disease during the follow-up period
(Table 2). When comparing rates of disease-free survival
between secretory carcinoma and acinic cell carcinoma
patients, no statistical significance was observed (Supple-
mentary Fig. 4).
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Status of gene alterations
Twenty tumor tissue samples consisting of secretory carci-
nomas (17 ETV6 translocation-positive and 3 ETV6
translocation-negative secretory carcinomas) were subjected
to targeted deep sequencing analyses. Genetic variants were
selected for screening if they were pathogenic, likely
pathogenic, of uncertain significance in the ClinVar varia-
tion report (https://www.ncbi.nlm.nih.gov/clinvar), and
among those observed in human cancers (Fig. 3 and Sup-
plementary Table 2).
In our series, four genes were identified as pathogenic or
likely pathogenic. These included missense mutations and
splice site mutations in PRSS1 (c.47C>T; p.A16V), MLH1
(c.1151T>A; p.V384D),MUTYH (c.934-2A>G; splice site),
and STK11 (c.842C>T; p.P281L). The most commonly
detected pathogenic variant was the mutation in the PRSS1
gene, which was detected in 40% (8/20; 7/17 of ETV6
translocation-positive and 1/3 of ETV6 translocation-
negative secretory carcinomas). Mutations in MLH1 and
MUTYH were noted in secretory carcinoma (n= 2 and 1,
respectively), and serine/threonine kinase 11 (STK11), a
gene associated with the phosphatidylinositol 3-kinase
(PI3K) pathway, was observed (n= 1) [35]. As a variant
of uncertain significance, KMT5A (c.290-3C>A; splice site)
mutations were recurrently observed in 25% (5/20) of
secretory carcinomas. Although rare, several variants of
uncertain significance were noted in secretory carcinoma;
these were mutations in PALB2 (c.2329G>A; p.D777N),
RET (c.2611G>A; p.V871I), BRCA2 (c.6029T>G; p.
V2010G), APC (c.1276G>T; p.A426S), NBN (c.505C>T; p.
R169C), and BRIP1 (c.485G>A; p.R162Q) (Fig. 3). None
showed a significant copy number alteration.
Clinical implications of gene alterations
The tested cases were divided into two groups. The cases
were classified into the aggressive group (9 secretory car-
cinomas) if they had at least one of following features: the
presence of lymph node metastasis, were classified as
American Joint Committee on Cancer stage III, and/or had
tumor recurrence during the observation period. The cases
classified into the indolent group (11 secretory carcinomas)
did not include any of the above-mentioned features. The
Fig. 1 Histopathological features of secretory carcinoma. Tumors
frequently show papillary cystic (a) and microcystic (b) growth
architectures. The tumor cells show low-grade uniform nuclei, occa-
sional small nucleoli, and pinkish bubbly cytoplasm (c). Mucin-like
and/or eosinophilic secretions are easily detected in tumors with
microcystic growth patterns (b, d). The tumors showed expression of
S100 (e) and mammaglobin (f) and no expression of DOG1 (g). An
ETV6 break-apart FISH assay showed a split of one red signal and one
green signal per nucleus, indicative of ETV6 translocation (H: yellow
arrow) with a fusion signal (H: gray arrow). The images in A through
G were captured at ×100 and ×400 magnification.
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genetic alterations analyzed in each group are represented in
Fig. 4.
The mutation frequency of PRSS1 was 56% (5/9) in the
aggressive group and 27% (3/11) in the indolent group.
Mutations in MLH1 and MUTYH genes are involved in
DNA repair and the development of cancers, especially
colorectal cancer (ClinVar; https://www.ncbi.nlm.nih.gov/
clinvar/) [36]. Mutations in these genes were only observed
in the aggressive group. The KMT5A gene is involved in
histone modification due to its function as a histone
methyltransferase [37] (ClinVar; https://www.ncbi.nlm.nih.
gov/clinvar/). Although a variant of uncertain significance,
KMT5A was found to have a mutation rate of 44%
(4/9) in the aggressive group and 9% (1/11) in the
indolent group.
Results of RNA fusion gene analysis
The RNA extracted from the formalin-fixed paraffin-
embedded tissues was severely degraded, and RNA quality
was very low. Nevertheless, RNA fusion gene analyses
detected several gene fusion types. The fusion variant of
ETV6- NTRK3 was noted in 4 out of 17 ETV6 translocation-
positive secretory carcinomas, which were defined by FISH
assays. This fusion variant was not detected in any of the
3 ETV6 translocation-negative secretory carcinomas.
Fig. 2 Histologic features of acinic cell carcinoma and ETV6
translocation-negative secretory carcinoma. Features of typical
acinic cell carcinoma or blue dot tumor (a). Microcystic acinic cell
carcinoma showing focal zymogen granule-containing cells (b). The
tumor stroma is sometimes lymphocyte predominant (c). Typical
immunohistochemistry of acinic cell carcinoma showing DOG1
positivity (d). A case of ETV6 translocation-negative secretory carci-
noma showing microcystic architecture without definite zymogen
granules (E) and diffuse staining for S100 (f) and mammaglobin (g).
The tumor shows an intact ETV6 gene by FISH. Most tumor nuclei
show intact fusions (h, red and green signals; gray arrows). This case
showed STK11 gene mutation. Another case of ETV6 translocation-
negative secretory carcinoma showing microcystic architecture (i).
This case revealed no remarkable genetic alteration. Another ETV6
translocation-negative secretory carcinoma showing variegated archi-
tectures of predominantly papillary cystic, partly microcystic archi-
tecture, and focally solid growth patterns (j–l). This case showed
PRSS1 mutation. The tumor cells of those three ETV6 translocation-
negative secretory carcinomas showed low-grade uniform nuclei,
occasional small nucleoli, and pinkish bubbly cytoplasm (e, i–k).
Mucin-like and/or eosinophilic secretions are easily detected in tumors
with microcystic growth patterns (e, i, k). Further features of the three
cases of ETV6 translocation-negative secretory carcinoma are sum-
marized in Supplementary Fig. 3.
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Single-event fusion variants were identified (including
ETV6 with NTRK2, PAX5, or ABL1 and fusion scripts of
LPP- KMT2A, QKI- NTRK2, NUP214- ABL1, and BRAF-
MKRN1) with a read depth below 5. Details are summarized
in Supplementary Table 3.
Discussion
We characterized the novel recurrent somatic mutations in
secretory carcinoma using targeted deep sequencing ana-
lyses. To our knowledge, no recurrent genomic alterations
in secretory carcinoma, except for the ETV6 rearrangement,
have been reported.
In our screening for secretory carcinoma candidates, we
noted that zymogen granule-poor tumors that were initially
diagnosed as acinic cell carcinoma constituted the largest
source of secretory carcinomas, as reported in previous
studies [4–14]. Although secretory carcinoma is the disease
entity most commonly mimicked by acinic cell carcinoma
[2, 38], we confirmed that secretory carcinoma had several
distinct features. Clinically, patients with secretory carci-
noma had relatively frequent lymph node metastasis. In our
series, at least 4 out of 22 (18.2%) secretory carcinomas
were pathologically proven to be lymph node-positive. The
rates of lymph node metastasis have been reported in as
many as 25% cases in literatures [2]. A previous report
shows about 22% (4/18) of lymph node metastases among
patients with secretory carcinoma. Although statistical
significance was not determined when combining










Male: Female 14:8 14:22
Anatomical distribution
Parotid gland 20 (91%)a 35 (97%)
Minor salivary gland 1 (5%)a 1 (3%)
Submandibular gland 1 (5%)a 0





Superficial parotidectomy 13 (59%) 22 (61%)
Total parotidectomy 7 (32%) 13 (36%)
Mass excision 2 (9%) 1 (3%)
Lymph-node dissection
Performed 11 (50%) 5 (14%)
Not performed 11 (50%) 31 (86%)
Nodal metastasisb 4 out of 11 0 out of 5
Resection margin involvement 2 (9%) 3 (8%)
American Joint Committee on Cancer tumor stage
I (T1N0) 3 (14%)c 12 (33%)b
II (T2N0) 14 (64%)c 21 (58%)b
III (T3 or N1) 5 (23%)c 3 (8%)b
Post operative radiation therapy 8 (36%) 5 (14%)
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3-year recurrence ratee 5/18 (28%) 2/26 (8%)
5-year recurrence ratee 7/16 (44%) 4/17 (24%)
Died of disease 0 (0%) 0 (0%)
aThe percentages before rounding are 90.9%, 4.5%, and 4.5%,
respectively
bLymph-node metastasis was known only among cases undergoing
lymph node dissection. To avoid overestimation, the percentage was
not presented in this table
cThe percentages before rounding are 13.6%, 63.6%, and 22.7%,
respectively. In 11 patients without node dissection, clinical N stage
was considered as cN0
dThe percentages before rounding are 33.33%, 58.33%, and 8.33%,
respectively
eThree-year and five-year follow-up data were available for 18 and 16
patients with secretory carcinoma, respectively; and 26 and 17 patients
with acinic cell carcinoma, respectively






Single-round 15 (68%) 16 (44%)
Multi-lobulated 7 (32%) 20 (56%)
Tumor border
Pushing 14 (64%) 25 (69%)
Infiltrative 8 (36%) 11 (31%)
Dominant growth pattern
Solid 0 (0%) 29 (81%)
Microcystic 6 (27%) 7 (19%)
Papillary cystic 14 (64%) 0 (0%)
Cribrifrom 2 (9%) 0 (0%)
Tumor stroma
Sclerosis 22 (100%) 31 (86%)
Lymphocyte-rich 0 (0%) 5 (14%)
Zymogen granule
Prominent 0 (0%) 30 (83%)
Focally present 0 (0%) 6 (17%)
Absent 22 (100%) 0 (0%)
Lymphovascular invasion 0 (0%) 2 (6%)
Perineural invasion 2 (9%) 4 (11%)
Immunohistochemistry
DOG1 expression 2 (9%; focal) 36 (100%; 36 diffuse)
S100 expression 22 (100%; 21 diffuse and 1 focal) 0 (0%)
Mammaglobin expression 20 (91%; 17 diffuse and 3 focal) 0 (0%)
P63 expression 0 (0%) 0 (0%)
ETV6 gene
Translocated 19 (86%) Not done
Not translocated 3 (14%)
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additional cases with known nodal status from previously
reported cases, the proportion of secretory carcinoma cases
with nodal metastasis (17.6%, 6/34) remained slightly
higher than acinic cell carcinoma (3/38, 7.9%) [4, 16].
These findings suggest the need for greater attention to
neck lymph node metastasis in the treatment of patients
with secretory carcinoma, including the surgical evaluation
of lymph nodes. Furthermore, the aggressive clinical
course in some secretory carcinoma cases like as tumor
recurrence as shown in our series and other literatures
[1, 2, 4, 16–18] suggests that secretory carcinoma may
require risk stratification for patient treatment, despite the
possibility of secretory carcinoma being a low-grade sali-
vary gland carcinoma like acinic cell carcinoma. Histolo-
gically, we found the differential characteristics of
secretory carcinoma to be the papillary cystic growth
pattern, the lack of PAS+ zymogen granules, and the
distinct immunohistochemical profiles of S100 and/or
mammaglobin positivity as well as DOG1 negativity, as
previously described [2, 4–15, 21, 38].
The comprehensive targeted deep sequencing analyses of
the secretory carcinoma cases were performed using cancer-
related gene panels. These analyses revealed novel recurrent
somatic mutations, especially in the PRSS1 gene. Further-
more, our analyses provided biologic insight into genetic
alterations of secretory carcinoma.
The PRSS1 gene encodes a cationic trypsinogen, which
is a member of the trypsin family of serine proteases. This
enzyme, which aids in digestion, is secreted by the pancreas
and cleaved to its active form in the small intestine.
Germline and somatic mutations in the PRSS1 gene are
associated with hereditary pancreatitis, chronic pancreatitis,
and pancreatic adenocarcinoma. As a result of PRSS1 gene
mutations, trypsinogen is prematurely activated and cannot
be broken down because of the elimination of the trypsin
hydrolysis site. The resulting increase in trypsin is thought
to be associated with pancreatitis and pancreatic adeno-
carcinoma. The R117H mutation is a frequently observed
germline mutation in PRSS1. N29I, A16V, D22G, K23R,
A121T, and R122C mutations in the PRSS1 gene have also
been reported to be rare mutations in cationic trypsinogen
[39–43]. Among these mutations, we recurrently observed
the A16V(C→T) mutation in 40% (8/20) of secretory car-
cinoma cases. It may be the first identification of this
mutation in secretory carcinoma.
Pancreatic digestive enzymes, including trypsin, are also
expressed in salivary glands. Because both the pancreas and
salivary glands are exocrine glands with a very similar his-
tology [44, 45], the PRSS1 mutation and resulting abnormal
trypsinogen function may also be involved in the patho-
genesis of salivary gland cancer. The identification of a
recurrent A16V mutation in the PRSS1 gene in secretory
carcinoma is of clinical interest and warrants further in-depth
studies as well in other subtypes of salivary gland tumors.
Secretory carcinoma is most commonly reclassified from
zymogen granule-poor acinic cell carcinoma. Given that
zymogen granules contain many digestive enzymes, such as
trypsin, mutant PRSS1 may be involved in the tumorigen-
esis of this zymogen granule–poor cancer. ETV6-NTRK3
fusion may be associated with a secondary mutation in
Fig. 3 Landscape of the genetic
alterations identified by the
targeted deep sequencing
analysis for 20 secretory
carcinomas.
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PRSS1, as secretory carcinoma is characterized by ETV6
gene rearrangement, with its most common translocation
partner being the NTRK3 gene. There have been no studies
on the relationship between PRSS1, ETV6 (a transcription
repressor), and NTRK3 (a neurotropic tyrosine kinase).
However, in our series, 1 case of SC with an intact ETV6
gene had the PRSS1 mutation, suggesting that other
mechanisms may be involved in the PRSS1 mutation of
zymogen granule-poor cancers.
Genetic profiling showed that the secretory carcinomas
with intact ETV6 genes had genetic alterations that were not
significantly different from those of the secretory carcino-
mas with ETV6 gene translocation. In addition, the PRSS1
mutation was shared by both. Therefore, the typical his-
tology of secretory carcinoma, including the papillary cystic
and microcystic growth pattern, the lack of PAS+ zymogen
granules, and the distinct immunohistochemical profiles of
S100 and/or mammaglobin positivity [2, 4–15, 21, 38]
supported the diagnosis of secretory carcinoma.
The 3 ETV6 translocation-negative secretory carcinomas
originally diagnosed as zymogen granule-poor acinic cell
carcinoma posed a diagnostic dilemma. The International
Head and Neck Scientific Group recently proposed classi-
fying these tumors as a family of tumors rather than distinct
entities, such as carcinomas of intercalated duct-like cells in
microcystic, papillary follicular, cystic, and mixed archi-
tectural arrangement among the acinic-intercalated ductal
carcinoma [38]. In our series, however, we followed the
current suggestion [20] and grouped the 3 ETV6
translocation-negative cases as secretory carcinoma.
Detection of ETV6 by FISH is technically feasible and
has been described in most cases of secretory carcinoma
since its original description. However, there were several
reports showing that FISH did not detect ETV6 transloca-
tion in 5 to 14% of tested cases with typical histological
features of secretory carcinoma [10, 17, 20]. In our series,
14% (3/22) of secretory carcinomas failed to detect ETV6
translocation by FISH analyses, and RNA fusion gene
analyses also did not detect ETV6 gene fusion in those 3
cases. The negative results of ETV6 translocation by FISH
analysis may stem from technical limits.
Secretory carcinoma did not display highly diverse or
highly frequent pathogenic variants that are known to be
cancer genomes in highly malignant human cancers [46].
Rather, the low-grade, indolent behaviors of secretory car-
cinoma were observed. Nevertheless, cases with aggressive
clinicopathologic features, such as lymph node metastasis,
advanced American Joint Committee on Cancer stage, and
tumor recurrence, revealed some gene alterations of PRSS1,
MLH1, MUTYH, and KMT5A. These gene alterations may
Fig. 4 The genetic alteration
status between the case group
with aggressive
clinicopathologic features, such
as tumor recurrence, lymph
node, and/or advanced
American Joint Committee on
Cancer stage III, and the case
group of indolent features
showing no evidence of tumor
recurrence, lymph node
metastasis, or advanced
American Joint Committee on
Cancer stage III.
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help to classify the high risk group among patients diag-
nosed with secretory carcinoma.
A recent study has shown alternative ETV6 partners,
such as RET and MAML3, by using the targeted next-
generation sequencing assay [47]. Other studies have shown
ETV6-RET fusion by using reverse transcription polymerase
chain reaction [48]. Due to the low quality of RNA in our
series, we could not reliably identify fusion scripts. We only
observed the ETV6-NTRK3 fusion and the prototypical
fusion in secretory carcinoma [1, 2]. The fusion was
observed in 4 of ETV6 translocation-positive secretory
carcinoma, but not any of ETV6 translocation-negative
secretory carcinomas. As alternative fusion partners,
NTRK2, ABL1, and PAX5 were also identified, but the read
depth was too low and unreliable.
In addition to the ETV6 gene rearrangement, the A16V
mutation in PRSS1 was recurrently observed in secretory
carcinoma, which are generally low-grade indolent tumors.
However, cases with aggressive clinicopathologic features
have some recurrent gene alterations in PRSS1, MLH1,
MUTYH, and KMT5A. Regarding their distinct clinical and
histological features, including relatively frequent rates of
lymph node metastasis and tumor recurrence, these novel
genetic alterations may provide insight into the biological
pathogenesis of secretory carcinoma. They may also help to
improve current diagnostic methods, patient treatment
strategies, such as lymph node evaluation and follow-up for
tumor recurrence, clinical risk stratification of patients, and
therapeutic targets for recurrent intractable tumors.
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